Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR-γδT for R/R AML
NCT05388305Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Universal CD123 CAR-γδT cells in acute myeloid leukemia (AML), sponsored by Senlang Bio. Primary endpoint: Incidence and severity of adverse events at 1 month. Status: unknown.
02
Drugs
Universal CD123 CAR-γδT cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05388305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388305.